Menu
Content/Inhalt
Home
|
Careers
|
Contact us
Search
Welcome
History
Social responsibility
Our companies
Debiopharm Group
Debiopharm S.A.
Debio R.P. S.A.
Debioclinic S.A.
Debiovision Inc.
Debioinnovation S.A.
Business Model
Strengths
Development capabilites
Preclinical
Clinical
Manufacturing
Regulatory
Innovative drug delivery and formulation
Partnering
Licensing-in
Licensing-out
Partners
Pipeline
Commercial Products
Eloxatin®
Decapeptyl®
News & Events
Press Releases
Awards
Publications
Conferences
News
20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions
Home
News & Events
Press Releases
PRESS RELEASES
Order
Date asc
Date desc
Title asc
Title desc
Ordering
Display #
5
10
15
20
25
30
50
Date
Item Title
12-May-2004
Debiopharm exercises its Option and signs a License Agreement with the Shanghai Institute of Materia Medica for the Development and Commercialisation of ZT-1
05-Nov-2003
Debiopharm presents results of a first monthly injectable sustained-release fomulation of ZT-1 for Alzheimer´s Disease
19-Oct-2003
Debiopharm SA starts a Phase II trial for a once daily oral formulation of ZT-1 to treat Alzheimer´s
20-Jun-2002
H3 Pharma announces promising developments for the treatment of Alzheimer´s disease
< Prev
1
2
Next >
Results 6 - 9 of 9
Debio 0827
( 1 items )
Debio 0826
( 1 items )
Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®
( 10 items )
Debio 8609 Sanvar®
( 13 items )
Debio 025
( 5 items )
Debio 0614 (istaroxime)
( 2 items )
Debio 0507
( 3 items )
Debio 0719
( 1 items )
Debio 0617
( 2 items )
Oxaliplatin – Eloxatin® – Elplat®
( 10 items )
Moapar® - Salvacyl®
( 3 items )
Other News
( 47 items )
